The principals of Great Point Partners have a long history of helping executives build successful health care companies.
Business Model:
Revenue: $6.2M
Employees: 2-10
Address: 165 Mason Street 3rd Floor
City: Greenwich
State: CT
Zip: 06830
Country: US
The principals of Great Point Partners have a long history of helping executives build successful health care companies. Their investment team is augmented by their CEO Advisory Board and Medical Advisory Board, members of whom are available to provide advice and assistance to their entrepreneurs and their portfolio companies.
Contact Phone:
+12039713300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2004 | Forbes Medi-Tech | Series A | 10.8M |
9/2022 | iXCells Biotechnologies | Private Equity Round | - |
3/2011 | Cytovance Biologics | Venture Round | 22.5M |
5/2022 | JPA Health | Private Equity Round | - |
11/2007 | SGX Pharmaceuticals | Post-IPO Equity | 25M |
9/2021 | BioAtla | Post-IPO Equity | 0 |
9/2021 | Velentium | Venture Round | - |
5/2018 | Clinical Supplies Management | Debt Financing | - |
7/2022 | Ephicacy | Private Equity Round | - |
6/2019 | Bionova Scientific | Private Equity Round | - |
2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
8/2012 | Connecture | Venture Round | 20M |
9/2008 | APT Pharmaceuticals | Series B | 32M |
2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
2/2023 | Abivax | Post-IPO Equity | 0 |
3/2010 | BioSante Pharmaceuticals | Post-IPO Equity | 18M |
10/2018 | Nebula Genomics | Series A | 0 |
5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
5/2011 | Biodel | Post-IPO Equity | 30M |
11/2011 | Aris Radiology | Private Equity Round | - |
11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
12/2004 | Panacos Pharmaceuticals | Post-IPO Equity | 20M |
11/2013 | Health Revenue Assurance Holdings | Venture Round | 5.4M |
5/2011 | WaferGen Biosystems | Post-IPO Equity | 0 |
12/2013 | Bovie Medical | Post-IPO Equity | 7M |
10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
3/2010 | Solta Medical | Post-IPO Equity | 4.8M |
1/2010 | Solta Medical | Post-IPO Equity | 17.2M |
10/2007 | APT Pharmaceuticals | Series A | 22M |
6/2013 | iVantage Health Analytics | Private Equity Round | 10M |
8/2022 | Heron Therapeutics | Post-IPO Equity | 76.5M |
8/2008 | Biotronic NeuroNetwork | Private Equity Round | - |
7/2022 | Ephicacy | Private Equity Round | - |
5/2022 | JPA Health | Private Equity Round | - |
9/2021 | Velentium | Venture Round | - |
9/2021 | BioAtla | Post-IPO Equity | 0 |
5/2021 | Magenta Therapeutics | Post-IPO Equity | 0 |
2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
6/2019 | Bionova Scientific | Private Equity Round | - |
5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
10/2018 | Nebula Genomics | Series A | 0 |
5/2018 | Clinical Supplies Management | Debt Financing | - |
Name | Price |
---|
Name | Size | Announced Date |
---|